SiBone (NASDAQ:SIBN) CEO Sells $1,432,037.00 in Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 93,475 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $15.32, for a total value of $1,432,037.00. Following the sale, the chief executive officer owned 544,369 shares in the company, valued at $8,339,733.08. The trade was a 14.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

SiBone Stock Performance

NASDAQ:SIBN traded up $0.49 during midday trading on Wednesday, reaching $15.74. 569,275 shares of the company traded hands, compared to its average volume of 551,190. SiBone has a twelve month low of $12.49 and a twelve month high of $21.89. The company has a debt-to-equity ratio of 0.21, a current ratio of 7.97 and a quick ratio of 6.62. The company has a fifty day moving average price of $18.03 and a 200 day moving average price of $16.86. The firm has a market capitalization of $682.97 million, a price-to-earnings ratio of -30.86 and a beta of 0.69.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SIBN shares. Needham & Company LLC raised their price target on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. TD Cowen raised SiBone to a “strong-buy” rating in a report on Tuesday, January 27th. Truist Financial lifted their target price on SiBone from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Finally, Morgan Stanley raised their target price on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.33.

Institutional Investors Weigh In On SiBone

Several large investors have recently modified their holdings of SIBN. First Light Asset Management LLC boosted its position in shares of SiBone by 162.4% in the 4th quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock valued at $99,249,000 after purchasing an additional 3,115,001 shares during the period. American Century Companies Inc. raised its holdings in shares of SiBone by 22.5% during the third quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock valued at $41,777,000 after acquiring an additional 521,683 shares during the period. Vanguard Group Inc. lifted its position in shares of SiBone by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company’s stock valued at $49,331,000 after acquiring an additional 11,566 shares in the last quarter. Nuveen LLC grew its position in SiBone by 5.1% during the 4th quarter. Nuveen LLC now owns 1,421,946 shares of the company’s stock worth $28,041,000 after purchasing an additional 69,229 shares in the last quarter. Finally, Impax Asset Management Group plc raised its stake in SiBone by 17.1% during the 4th quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company’s stock valued at $23,664,000 after purchasing an additional 175,000 shares during the period. 98.11% of the stock is owned by institutional investors.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.